Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.




[Back to Overview]  [IACM Homepage]

TitleAcute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers.
Author(s)Martín-Santos R, Crippa JA, Batalla A, Bhattacharyya S, Atakan Z, Borgwardt S, Allen P, Seal M, Langohr K, Farré M, Zuardi AW, McGuire P.
Journal, Volume, IssueCurr Pharm Des. 2012 Jun 7. [Epub ahead of print]
Major outcome(s)CBD does not cause significant side effects
IndicationAbstract
MedicationDelta-9-THC;Cannabidiol

Rationale: Animal and humans studies suggest that the two main constituents of
cannabis sativa, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) have
quite different acute effects. However, to date the two compounds have largely
been studied separately. Objective: To evaluate and compare the acute
pharmacological effects of both THC and CBD in the same human volunteers.
Methods: A randomised, double-blind, cross-over, placebo controlled trial was
conducted in 16 healthy male subjects. Oral THC 10 mg or CBD 600 mg or placebo
was administered in three consecutive sessions, at one-month intervals.
Physiological measures and symptom ratings were assessed before, and at 1, 2 and
3 hours post drug administration. The area under the curve (AUC) between baseline
and 3 hours, and the maximum absolute change from baseline at 2 hours were
analyzed by one-way repeated measures analysis of variance, with drug condition
(THC or CBD or placebo) as the factor. Results: Relative to both placebo and CBD,
administration of THC was associated with anxiety, dysphoria, positive psychotic
symptoms, physical and mental sedation, subjective intoxication (AUC and effect
at 2 hours: p<0.01), an increase in heart rate (p<0.05). There were no
differences between CBD and placebo on any symptomatic, physiological variable.
Conclusions: In healthy volunteers, THC has marked acute behavioural and
physiological effects, whereas CBD has proven to be safe and well tolerated.

Route(s)Oral
Dose(s)10 and 600 mg
Duration (days)
Participants16 healthy subjects
DesignControlled study
Type of publicationMedical journal
Address of author(s)Department of Psychosis Studies, Institute of Psychiatry, King's College London, UK.
Full text

[Back to Overview]  [IACM Homepage]


up